The present study suggests that moluodan may increase serum gastrin by repairing gastrin-secreting cells and somatostatin-secreting cells in the gastric mucosa to treat CAG.[13] In addition, moluodan also significantly reduced the expression of EGF and EGFR in the serum of patients with CAG, thereby inhibiting further transformation of precancerous lesions in gastric cancer.[14] In recent years, an increasing number of clinical trials have suggested that moluodan has good efficacy in the treatment of CAG, but there are no relevant systematic evaluations and meta-analysis. Here, GAST is linked to gastric cancer.